Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Germany (DAX) (EWG) vs Eli Lilly And Co (LLY) Price & Performance

iShares MSCI Germany (DAX)Trade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Germany (DAX) vs Eli Lilly And Co — how do they compare? iShares MSCI Germany (DAX) trades at $41.98 (market cap $1.42B), while Eli Lilly And Co trades at $1,165.25 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 732.4× iShares MSCI Germany (DAX)'s market cap, and Eli Lilly And Co pays a 0.59% dividend while iShares MSCI Germany (DAX) pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 56 Days and Eli Lilly And Co for 93 Days on average.

EWGLLY
Market Cap
$1.42B$1.04T
Volume
1,110,5733,064,878
Sector
Broad Market / FactorHealth
52-Week High
$44.59$1.28K
52-Week Low
$38.08$799.57
Typical Hold Time
56 Days93 Days
Enterprise Value
—$1.09T
Dividend Yield
—0.59%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Germany (DAX)

EWG is trading at $40.91, down 1.4% with a bearish technical outlook showing 19 sell signals versus 1 buy. The stock faces resistance at $41 with support at $40. Technical indicators show oversold conditions with RSI at 25.94, but moving averages and oscillators remain bearish. Recent European market sentiment is mixed with ECB rate hikes and energy price concerns affecting regional equities.

Investment outlook remains cautious given the bearish technical signals and macroeconomic pressures from ECB tightening. The stock's proximity to support levels suggests potential for near-term stabilization, but sustained recovery requires improved fundamental performance and easing of European economic concerns.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,188.72, up 2.7% today, reflecting strong momentum driven by robust earnings beats and bullish technical signals. The stock exhibits impressive fundamentals with 2025 revenue of $65.18B and net income of $20.64B, yielding a net margin of 31.66%. Recent news highlights promising pipeline developments in weight-loss drugs, including EloraTZP, which outperformed Zepbound in trials, reinforcing its competitive edge in the obesity and diabetes markets.

Outlook remains positive given analyst consensus of a $1,350 price target and 73% buy ratings, though high valuation multiples (P/E 39.26) and rising debt-to-asset ratios (42.78% in 2024) warrant caution. Key risks include regulatory hurdles and intensifying competition from rivals like Novo Nordisk, but Lilly's innovation pipeline and market leadership position it for sustained growth.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EWG

No sentiment data available yet.

LLY
69% Buy31% Sell
Avg holding period · 93 Days

Top news

Latest headlines on both assets

About iShares MSCI Germany (DAX)

EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.

Read more on EWG →

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY →